Clinical trials: Respiratory Synctial Virus
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Respiratory Synctial Virus Infections
Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.
This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy.
- Trial name
- NCT06856967
- Testing
- Nirsevimab
- Where
- 8 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Meyer Children's Hospital IRCCS
Respiratory Synctial Virus
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
This is a randomized, observer-blind, irrelevant comparator-controlled trial in male and female subjects ≥24 months of age and <72 months of age.
- Trial name
- NCT02296463
- Testing
- RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccine (0.5mL injection), Hepatitis A Vaccine (0.5mL injection)
- Where
- 4 sites in Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novavax
Respiratory Synctial Virus, Asthma Childhood
Infant RSV Immunity Study
Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection.
- Trial name
- IRIS (NCT07653347)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Respiratory Synctial Virus Infections
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in…
- Trial name
- NCT06775405
- Testing
- AK0529
- Where
- 17 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.